DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
https://www.zacks.com/stock/news/2257798/diamedica-dmac-up-as-stroke-study-dosing-begins-post-relaunch?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2257798
Apr 18, 2024 - DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.
0
CoStar Group (CSGP) to Post Q1 Earnings: What's in Store?
https://www.zacks.com/stock/news/2258714/costar-group-csgp-to-post-q1-earnings-what-s-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2258714
Apr 19, 2024 - CoStar Group's (CSGP) first-quarter 2024 top line is likely to reflect a robust portfolio of marketplaces, which includes Apartments.com, LoopNet and Homes.com.
0
Lam Research (LRCX) to Post Q3 Earnings: What's in the Cards?
https://www.zacks.com/stock/news/2258614/lam-research-lrcx-to-post-q3-earnings-what-s-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_preview-2258614
Apr 19, 2024 - Lam Research's (LRCX) third-quarter fiscal 2024 results are expected to reflect strength in 3D DRAM and advanced packaging amid a slowdown in memory spending.
0
Netflix ETFs to Buy on the Dip Post Solid Q1 Earnings
https://www.zacks.com/stock/news/2258499/netflix-etfs-to-buy-on-the-dip-post-solid-q1-earnings?cid=CS-ZC-FT-etf_news_and_commentary-2258499
Apr 19, 2024 - Netflix (NFLX) topped both earnings and revenue estimates and delivered its strongest first-quarter customer additions since the pandemic. However, it issued disappointing second-quarter revenue guidance, which dragged the stock down.
0
Schwab And Netflix Post-Earnings: Both Stocks Still Well Off All-Time '21 Highs
https://seekingalpha.com/article/4685173-schwab-and-netflix-post-earnings-both-stocks-still-well-off-all-time-21-highs?source=feed_all_articles
Apr 22, 2024 - Schwab is still battling the inverted yield curve, and the need to pay their clients a 5.35% money market yield
0
Snap-On: A Good Buy Post The Recent Correction
https://seekingalpha.com/article/4685167-snap-on-a-good-buy-post-the-recent-correction?source=feed_all_articles
Apr 22, 2024 - Snap-on revenues are expected to recover with easing year-over-year comparisons and strategic adjustments in the Tools segment. See why SNA stock is rated buy.
0
Otis Worldwide (OTIS) to Post Q1 Earnings: Factors to Note
https://www.zacks.com/stock/news/2259541/otis-worldwide-otis-to-post-q1-earnings-factors-to-note?cid=CS-ZC-FT-analyst_blog|earnings_preview-2259541
Apr 22, 2024 - Otis Worldwide's (OTIS) first-quarter 2024 performance is likely to have benefited from strong volume and favorable pricing. Yet, currency fluctuations are a concern.
0
Rockwell Automation (ROK) to Post Q2 Earnings: What's in Store?
https://www.zacks.com/stock/news/2259409/rockwell-automation-rok-to-post-q2-earnings-what-s-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2259409
Apr 22, 2024 - Rockwell Automation's (ROK) second-quarter fiscal 2024 performance is likely to reflect the impact of the ongoing supply-chain issues and elevated costs.
0
Eastman Chemical (EMN) to Post Q1 Earnings: What's in Store?
https://www.zacks.com/stock/news/2260537/eastman-chemical-emn-to-post-q1-earnings-what-s-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2260537
Apr 23, 2024 - Eastman's (EMN) cost-cutting initiatives and innovation are anticipated to have benefited the company in Q1.
0
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
https://www.zacks.com/stock/news/2260461/corcept-cort-posts-positive-data-from-cushing-s-syndrome-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2260461
Apr 23, 2024 - Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.
0